Modality
Bispecific Ab
MOA
MALT1i
Target
AuroraA
Pathway
Proteasome
AMLEndometrial Ca
Development Pipeline
Preclinical
~Aug 2022
→ ~Nov 2023
Phase 1
Feb 2024
→ Mar 2027
Phase 1Current
NCT07130372
1,867 pts·Endometrial Ca
2025-07→TBD·Not yet recruiting
NCT07273489
2,555 pts·Endometrial Ca
2024-02→2027-03·Recruiting
4,422 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-2812mo awayPh2 Data· Endometrial Ca
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2027-03-28 · 12mo away
Endometrial Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07130372 | Phase 1/2 | Endometrial Ca | Not yet recr... | 1867 | Mayo |
| NCT07273489 | Phase 1/2 | Endometrial Ca | Recruiting | 2555 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ARG-6988 | Argenx | Preclinical | AuroraA |